Health Technology · Pharmaceuticals: Major · NSE: CURIS · data 2026-10-09

Curis Lifesciences Limited

Health check: Strong (8.9/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹202

Market cap

₹163 cr

P/E

23.8

P/B

3.5

ROE

21.7%

ROCE

26.6%

Debt / equity

0.46

Dividend yield

0.00%

1-year return

38.3%

52-week high

₹234.75

52-week low

₹83.6

Operating margin

17.2%

Growth

Revenue (last 12 months)	₹61 cr
Net profit (last 12 months)	₹7 cr
Sales growth, 3 years (yearly)	19.6%
Profit growth, 3 years (yearly)	78.0%

Similar companies

Nectar Lifesciences Ltd. (NECLIFE) · Accretion Pharmaceuticals Ltd. (ACCPL) · Medico Remedies Ltd. (MEDICO) · Bal Pharma Limited (BALPHARMA) · Quest Laboratories Ltd. (QUESTLAB)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open CURIS in NSE Scanner →